摘要
目的:通过临床总结及相关文献复习,了解131I标记间碘苄胍(131I-MIBG)在神经母细胞瘤治疗中的地位。方法:回顾性分析北京儿童医院收治的3例高危神经母细胞瘤患儿的临床特点、既往治疗以及131I-MIBG治疗的疗效并进行相应文献复习。结果:2例患儿部分缓解,另1例未缓解、但肿瘤略有缩小。患儿的发热、骨痛症状明显缓解。3例患儿治疗后均出现II度骨髓抑制,可自行恢复,未出现高血压反应,但出现Ⅱ度恶心、呕吐等消化道反应,经治疗好转。结论:131I-MIBG治疗的副作用小,耐受性好,改善症状明显,疗效肯定。131I-MIBG可以作为复发的高危神经母细胞瘤患儿的治疗选择。
Objective：To understand the role of 131I-metaiodobenzylguanidine（131I-MIBG）in treatment of neuroblastoma through summarizing three cases of clinical data of patients with refractory high risk neuroblastoma and reviewing relative articles.Methods：Retrospectively analysis the clinical characteristics,history of treatments,and 131I-MIBG therapy of three high risk neuroblastoma patients from the affiliated Beijing Children＇s Hospital,Capital University of Medical Sciences.Results：Two patients were partial response and 1 patient was stable with decrease of tumor volume after treatment of 131I-MIBG.Symptoms of fever and bone pain were obviously relieved.Three patients experienced grade 2 bone suppression which could be recovered spontaneously.Three patients experienced grade 2 nausea and vomiting which could be recovered after treatment.All patients showed no hypertension after treatment of 131I-MIBG.Conclusion：Treatment with 131I-MIBG had certain efficacy with slight side effects and being well tolerated by patients,as well as obviously improving the symptoms of patients.131I-MIBG should be a choice of treatment to patients with refractory high risk neuroblastoma.
出处
《中日友好医院学报》
2011年第3期148-151,共4页
Journal of China-Japan Friendship Hospital
关键词
神经母细胞瘤
复发
高危
131I
间腆苄胍
neuroblastomoa
refractory
high risk
131I
metaiodobenzylguanidine
